Asset Details
Do you wish to reserve the book?
Depression in Parkinson's Disease: Symptom Improvement and Residual Symptoms After Acute Pharmacologic Management
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Depression in Parkinson's Disease: Symptom Improvement and Residual Symptoms After Acute Pharmacologic Management
Do you wish to request the book?
Depression in Parkinson's Disease: Symptom Improvement and Residual Symptoms After Acute Pharmacologic Management
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Depression in Parkinson's Disease: Symptom Improvement and Residual Symptoms After Acute Pharmacologic Management
2011
Overview
Parkinson's disease (PD) is frequently complicated by depression and there is a paucity of controlled research that can inform the management of this disabling nonmotor complaint. A randomized controlled trial of nortriptyline, paroxetine, and placebo for the treatment of depression in PD (dPD) was recently completed. The purpose of this article is to describe the baseline pattern of depressive symptom presentation in PD, the specific symptoms of dPD that improve with pharmacotherapy, and the residual symptoms that remain in patients who meet a priori criteria for response or remission after acute treatment (8 weeks).
The Departments of Psychiatry and Neurology at Robert Wood Johnson Medical School, New Jersey.
Fifty-two depressed patients (major depression or dysthymia based on Diagnostic and Statistical Manual of Mental Disorders 4th edition criteria) with Parkinson's disease (by research criteria).
A randomized controlled trial of nortriptyline, paroxetine, and placebo.
The four subscales (core mood, anxiety, insomnia, and somatic) and individual items from the Hamilton Rating Scale for Depression-17 were the focus of this study. These measures were assessed at baseline and Week 8.
Baseline depressive symptoms were unrelated to motor functioning. Treatment response was associated with significant improvements in the core mood, anxiety, insomnia, and somatic symptoms seen in dPD. Residual symptoms, such as sadness and loss of interest, persisted in treatment responders in a milder form than was initially present.
Antidepressants may influence all symptoms of dPD, including those that share great overlap with the physical disease process. Additional research regarding adjunctive interventions is needed to help optimize the management of dPD. (Am J Geriatr Psychiatry 2011; 19:222–229)
Publisher
Elsevier Inc,Elsevier Limited
Subject
/ Antidepressive Agents - therapeutic use
/ Anxiety
/ Criteria
/ Depressive Disorder, Major - complications
/ Depressive Disorder, Major - diagnosis
/ Depressive Disorder, Major - drug therapy
/ Diagnostic and Statistical Manual
/ Disease
/ Dysthymic Disorder - complications
/ Dysthymic Disorder - diagnosis
/ Dysthymic Disorder - drug therapy
/ Emotions
/ Female
/ Humans
/ Insomnia
/ Male
/ Measures
/ Nortriptyline - therapeutic use
/ Parkinson Disease - complications
/ Parkinson Disease - drug therapy
/ Paroxetine - therapeutic use
/ Patients
/ Placebos
/ Psychiatric Status Rating Scales
/ Sadness
/ Symptoms
